Your browser is no longer supported. Please, upgrade your browser.
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E36.70 EPS (ttm)4.27 Insider Own0.30% Shs Outstand219.10M Perf Week-0.41%
Market Cap33.93B Forward P/E12.09 EPS next Y12.96 Insider Trans-3.79% Shs Float218.11M Perf Month-0.77%
Income956.60M PEG3.34 EPS next Q2.56 Inst Own93.40% Short Float1.62% Perf Quarter28.41%
Sales5.86B P/S5.79 EPS this Y15.00% Inst Trans-0.16% Short Ratio1.43 Perf Half Y43.45%
Book/sh50.55 P/B3.10 EPS next Y6.98% ROA5.50% Target Price173.65 Perf Year39.28%
Cash/sh10.61 P/C14.77 EPS next 5Y11.00% ROE8.60% 52W Range72.67 - 160.03 Perf YTD0.29%
Dividend- P/FCF12.95 EPS past 5Y26.80% ROI16.90% 52W High-2.08% Beta1.25
Dividend %- Quick Ratio3.30 Sales past 5Y17.40% Gross Margin91.20% 52W Low115.63% ATR2.96
Employees3082 Current Ratio3.80 Sales Q/Q25.80% Oper. Margin9.40% RSI (14)68.98 Volatility0.88% 1.11%
OptionableYes Debt/Eq0.23 EPS Q/Q25.80% Profit Margin16.30% Rel Volume0.84 Prev Close156.65
ShortableYes LT Debt/Eq0.22 EarningsOct 29 BMO Payout0.00% Avg Volume2.46M Price156.70
Recom2.70 SMA200.46% SMA5013.93% SMA20034.93% Volume2,079,845 Change0.03%
Dec-16-20Downgrade Truist Buy → Hold $175
Dec-14-20Downgrade Wedbush Outperform → Neutral $175
Dec-14-20Downgrade Robert W. Baird Outperform → Neutral $175
Dec-14-20Downgrade Credit Suisse Outperform → Neutral $147 → $194
Dec-14-20Downgrade BMO Capital Markets Outperform → Market Perform $152 → $175
Oct-28-20Initiated UBS Neutral $133
Sep-01-20Resumed Stifel Hold $120 → $117
Jul-31-20Downgrade William Blair Outperform → Mkt Perform
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Jan-15-21 10:30AM  
08:24AM  
Jan-14-21 04:43PM  
10:35AM  
06:31AM  
Jan-13-21 06:38PM  
04:20PM  
10:08AM  
Jan-12-21 07:00AM  
Jan-11-21 08:40AM  
Jan-07-21 01:55PM  
11:40AM  
Jan-06-21 04:54PM  
Jan-05-21 04:30PM  
11:26AM  
Jan-04-21 05:55PM  
Jan-02-21 08:09AM  
Jan-01-21 12:53PM  
Dec-31-20 06:00PM  
Dec-30-20 08:49PM  
Dec-24-20 10:59AM  
Dec-23-20 09:00PM  
01:30PM  
07:36AM  
Dec-21-20 07:56PM  
03:40AM  
Dec-19-20 02:15PM  
Dec-18-20 09:00PM  
Dec-16-20 07:45PM  
01:37PM  
01:01PM  
06:34AM  
Dec-15-20 07:45PM  
04:13PM  
10:40AM  
10:31AM  
10:10AM  
09:43AM  
Dec-14-20 07:25PM  
07:07PM  
06:20PM  
05:28PM  
05:13PM  
04:51PM  
04:41PM  
04:05PM  
04:00PM  
02:53PM  
02:51PM  
02:18PM  
01:07PM  
12:56PM  
12:42PM  
12:11PM  
12:10PM  
11:35AM  
11:08AM  
11:07AM  
10:13AM  
10:12AM  
10:01AM  
09:53AM  
09:49AM  
09:46AM  
08:49AM  
08:41AM  
08:29AM  
08:25AM  
07:07AM  
05:15AM  
Dec-13-20 08:58PM  
Dec-12-20 07:00PM  
07:00PM  
02:42PM  
12:02PM  
11:09AM  
11:08AM  
10:24AM  
09:07AM  
08:27AM  
07:48AM  
Dec-11-20 05:50PM  
Dec-09-20 05:51AM  
Dec-07-20 10:24AM  
Dec-01-20 05:32AM  
Nov-30-20 12:19PM  
Nov-29-20 05:51AM  
Nov-24-20 03:14PM  
Nov-20-20 09:32AM  
02:00AM  
Nov-17-20 07:08AM  
05:47AM  
Nov-16-20 09:35AM  
Nov-13-20 10:40AM  
10:31AM  
Nov-11-20 03:15AM  
Nov-10-20 07:30AM  
07:00AM  
Nov-05-20 06:43PM  
Nov-04-20 03:32PM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bazarko DanielSVP, Controller, CAODec 17Option Exercise117.0424,0662,816,74054,949Dec 21 05:00 PM
Bazarko DanielSVP, Controller, CAODec 17Sale157.7024,0663,795,23330,883Dec 21 05:00 PM
Carino TanishaEVP & CCAODec 03Sale122.261,530187,05816,102Dec 04 04:47 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale114.696,853785,98128,218Jun 09 05:05 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM